Phlegm-Busting Drug Shows Promise in Parkinson’s

Phlegm-Busting Drug Shows Promise in Parkinson’s

Publication date: Jan 14, 2020

In a small, open-label, single-center study of Parkinson’s patients, ambroxol crossed the blood-brain barrier and boosted β-glucocerebrosidase (GCase) enzyme protein levels, reported Anthony Schapira, MD, DSc, of University College London, and colleagues in JAMA Neurology.

“The results of the AiM-PD study indicate that ambroxol is safe, well tolerated, and able to increase GCase levels in the spinal fluid of people with Parkinson’s,” Schapira told MedPage Today.

Although GCase activity is reduced in Parkinson’s patients with and without GBA1, it’s lower in people with the mutations.

In this nonrandomized, non-controlled trial, Schapira and colleagues treated 18 Parkinson’s patients with escalating doses of oral ambroxol to 1. 26 g per day (420 mg 3 times a day) from January 2017 to April 2018.

Concepts Keywords
420 Day Alpha
AiM Lysosome
Autopsies Alpha-synuclein
Blood Lysosomal storage disease
Blood Brain Barrier Expectorants
California Amines
Cerebrospinal Fluid Ambroxol
Chaperones Lewy body dementia
Confidence Limit Peripheral membrane proteins
Cough Syrup Enzymes
Dopaminergic Proteins
DSc Branches of biology
Enzyme Ambroxol drug cough
Genetic
London
Lysosomal Storage Disorder
Lysosome
Mice
Microscope
Neuroprotective
Parkinson
Phlegm
Risk Factor
Spinal Fluid
Stanford

Semantics

Type Source Name
drug DRUGBANK Ambroxol
drug DRUGBANK Nonoxynol-9
disease MESH risk factor
pathway KEGG Lysosome
disease MESH men

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *